000650 仁和药业
2026/03 - 三个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入1,129,22414.57%3,536,4224,074,8935,032,1465,153,215
减:营业总成本892,9939.35%2,913,9533,362,2324,045,0634,208,237
    其中:营业成本714,75714.83%2,229,2342,528,8813,164,0923,266,277
               财务费用(538)-42.90%393(10,312)(24,925)(23,065)
               资产减值损失1-98.79%(129,175)(113,320)(223,111)(68,739)
公允价值变动收益(2,427)14,439.87%25,11716,03416,82822,115
投资收益5,498-62.71%83,43072,70259,26146,314
    其中:对联营企业和合营企业的投资收益(1,130)17.05%(3,569)(4,831)(915)1,803
营业利润243,032-2.34%665,212774,986898,635953,263
利润总额242,907-2.20%664,897774,618898,860953,540
减:所得税费用64,67725.24%177,240208,033269,450241,997
净利润178,230-9.41%487,657566,586629,410711,542
减:非控股权益37,85516.74%94,44984,67462,153137,112
股东净利润140,375-14.57%393,208481,912567,257574,430

市场价值指针
每股收益 (元) *0.100-14.57%0.2800.3500.4100.410
每股派息 (元) *----0.1500.1500.2000.200
每股净资产 (元) *4.6121.80%4.5114.4104.2814.101
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容